Faruqi & Faruqi represents a proposed class of direct purchasers of Takeda Pharmaceuticals’ Colcrys, a prescription drug used for the treatment of Familial Mediterranean Fever and for the treatment and prevention of gout flares. The complaint alleges one or more conspiracies among Takeda, Par, Amneal, and Watson to unlawfully preserve Takeda’s Colcrys monopoly and to delay full generic competition.
Send Information
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.
Details
Filed on 08/05/2021
Office
1617 JFK Boulevard, Suite 1550
19103 Philadelphia, Pennsylvania
Phone (215) 277-5770
Fax (215) 277-5771
Counsel
Joseph T. Lukens jlukens@faruqilaw.com Phone (215) 277-5770 Fax (215) 277-5771
Peter Kohn pkohn@faruqilaw.com Phone (215) 277-5770 Fax (215) 277-5771